Want to see CRBU full AI Analyst Report?
CRBU Stock Chart & Stats
$1.65
$0.05(3.50%)
At close: 4:00 PM EDT
$1.65
$0.05(3.50%)
Day’s Range― - ―
52-Week Range$0.44 - $3.54
Previous CloseN/A
Volume203.30K
Average Volume (3M)3.97M
Market Cap
$55.64M
Enterprise Value$92.08M
Total Cash (Recent Filing)$112.31M
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding107,207,510
10 Day Avg. Volume9,567,613
30 Day Avg. Volume3,974,960
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue9.18
Enterprise Value/Gross Profit-7.07
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$3.75Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$9.17M
Bulls Say, Bears Say
Bulls Say
Genome-editing PlatformCaribou’s CRISPR-based chRDNA platform and focus on allogeneic, off-the-shelf immune-cell products provide a differentiated development foundation. If translated into viable therapies, this approach could support scalable product manufacturing and a broader oncology pipeline over time.
Manageable LeverageDebt remains modest relative to equity, with TTM debt-to-equity of about 0.27. This gives Caribou more balance-sheet flexibility than a highly leveraged biotechnology company, although continuing losses and asset declines still constrain that advantage.
Reduced Losses And Cash BurnThe company has narrowed net losses compared with 2024–2025, while cash burn has also improved from prior annual periods. This indicates some progress in cost control, potentially extending financial runway if management can sustain the reduction in spending.
Bears Say
Severe UnprofitabilityCaribou’s current revenue base is far too small to cover its cost structure: gross profit is negative and net losses are roughly ten times revenue. This weak operating model limits internally funded growth and leaves future progress dependent on successful financing or strategic action.
Persistent Cash BurnSubstantially negative operating and free cash flow remain a major structural weakness, with free cash flow deteriorating year over year. Because cash burn broadly tracks net loss, the company has limited non-cash offsets and may require external funding if losses continue.
Program DiscontinuationsStopping development and clinical activities for vispa-cel and CB-011 removes key pipeline programs despite reported safety, efficacy, and regulatory momentum. The decision materially narrows the operating platform and increases uncertainty around Caribou’s remaining strategic path.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.44 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $55.64M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Mar 11, 2027 which is in 140 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.084.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 107,207,510 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went down -1.863%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.75 (127.27% Upside)
$3.75 (127.27% Upside)
Blogger Sentiment
Neutral
CRBU Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.84%
12-Months-Change
Fundamentals
Return on Equity
-89.11%
Trailing 12-Months
Asset Growth
-35.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$3.75
▲(127.27% Upside)
Technical Analysis
Ownership Overview
4.31% Insiders
5.38% Mutual Funds
0.88% Other Institutional Investors
77.08% Public Companies and
Individual Investors